Market Research Future (MRFR)’s recent study projects that the global bladder cancer market size is set to expand saliently at a robust CAGR of 12.5% during the forecast period 2017 to 2023. The rising burden of bladder cancer coupled with technological advancements in the healthcare sector is anticipated fuel growth in the market.
The risk factors related to bladder cancer such as continuous exposure to radiation, chronic bladder infection, tobacco consumption, and excessive smoking are expected to fuel demand in the bladder cancer market. Other factors responsible for favoring the bladder cancer market growth are drug innovations, the rise in aging population, government initiatives, advanced health care services, increasing healthcare expenditure, etc.
The restraints to the market growth that are expected to hold the revenue generation over the next couple of years include asymptomatic nature of the disease, drug patent expirations, high costs of therapies, the rise in the use of generic drugs, etc.
Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/1899
By type, the global bladder cancer market has been segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer, adenocarcinoma, and others.
By treatment, the bladder cancer market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and others.
By diagnosis, the global bladder cancer market has been segmented into urine lab tests, cystoscopy, biopsy, imaging tests, and others.
By end-user, the bladder cancer market is segmented into hospitals, clinics, cancer care centers, and others.
On the basis of the geography, the global bladder cancer market is segmented into the four major regions, namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas holds the largest share in the global bladder cancer market. Presence of huge patient population suffering from bladder cancer is a major reason behind the same. As per the American Cancer Society, approximately 79,030 new cases of bladder cancer were reported in 2017. Moreover, it was estimated that the disease caused about 16,870 deaths withihn the U.S. Additionally, factors includfing changing lifestyle, rising government support, incrteasing role of cancer care organisations for incraesing the awareness s also impacts a positive growth in the global bladder cancer market.
Europe accounts for the second largest market share for the bladder cancer, which is followed by Asia Pacific. Asia Pacific is the fastest growing market owing to the huge population base, increasing prevalence of bladder cancer, rapidly developing economies and presence of huge opportunity for the growth of the market. The Middle East & Africa has the least market share due to the unavailability of the required healthcare infrastructure, lack of awareness among people, and affordability issues due to presence of the poor economies in Africa region.
Some of the key players profiled in the report are Bristol-Myers Squibb Company (U.S.), Celgene Corporation (U.S.), AstraZeneca Plc. (U.K.), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.S.), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (U.S.), Sanofi S.A. (France), Accord Healthcare (U.S.), Bedford Lab (U.S.), and Merck & Co. Inc. (U.S.).
In August 2018, Agilent Technologies, American public research, development, and manufacturing company, announced that it has received FDA approval for its test, PD-L1 IHC 22C3 pharmDx assay, which can be used for the identification of bladder cancer patients who might benefit from Keytruda.
In September 2018, it has been announced that BREATHALYSERS, breath test for cancer detection, will be available in GP surgeries within a few years. Initially, it will be used for detecting lung, bowel, esophagus and stomach cancer and will be expanded to the bladder, pancreas, and prostate later on.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Browse Complete Report @ https://www.marketresearchfuture.com/reports/bladder-cancer-market-1899
Related reports link:-
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312